- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| OBSIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Obsidian Therapeutics Completes Galera Merger And $350 Million Private Placement | 1 | pulse2.com | ||
| Mi | Piper Sandler initiates Obsidian Therapeutics stock with overweight | 2 | Investing.com | ||
| Mi | Piper Sandler startet Coverage für Obsidian Therapeutics Aktie mit "Overweight" | 1 | Investing.com Deutsch | ||
| Mi | RTW Biotech Opp. - Obsidian Therapeutics merges with Galera | 2 | RNS | ||
| Di | Galera Therapeutics, Inc. - 15-12G, Securities registration termination | 1 | SEC Filings | ||
| Mo | Obsidian Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| Mo | Obsidian Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| Mo | Obsidian Therapeutics Completes Galera Therapeutics Merger with $350M Private Placement Financing | 2 | Contract Pharma | ||
| Mo | Obsidian Therapeutics completes merger with Galera | 1 | Investing.com | ||
| Mo | Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million | 199 | Business Wire | • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
• Post-transaction cash and cash equivalents... ► Artikel lesen | |
| 31.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.07. | Galera Therapeutics, Inc. - 8-K, Current Report | 11 | SEC Filings | ||
| 15.05. | Galera Therapeutics, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Galera Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 19.04. | Obsidian Therapeutics, Galera Therapeutics Merger Comes With $350M Infusion for Cancer Drug Trials | 3 | MedCity News | ||
| 15.04. | Obsidian Therapeutics, Galera Therapeutics to advance cell therapy following reverse merger | 4 | BioPharma Dive | ||
| 15.04. | Obsidian Therapeutics To Merge With Galera Therapeutics In Reverse Merger | - | RTTNews | ||
| 15.04. | Obsidian Therapeutics to go public via Galera Therapeutics merger | 2 | Investing.com | ||
| 15.04. | Fusion mit Galera Therapeutics: Obsidian Therapeutics strebt Börsengang an | 3 | Investing.com Deutsch | ||
| 15.04. | RTW Biotech Opp. - Obsidian Therapeutics reverse merger with Galera Therapeutics | - | RNS |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 46,430 | +0,32 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| NOVOCURE | 13,700 | -3,32 % | Novocure Reports Second Quarter 2026 Financial Results | Quarterly net revenues of $184 million, an increase of 16% year-over-year, driven by 18% global active patient growth across indications
CE Mark received for Optune Paxfor the treatment of locally... ► Artikel lesen | |
| SPERO THERAPEUTICS | 1,092 | -0,18 % | Spero Therapeutics, Inc.: Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 | ||
| PRECISION BIOSCIENCES | 6,340 | -2,46 % | PRECISION BIOSCIENCES INC - S-8, Securities to be offered to employees in employee benefit plans | ||
| BOLT BIOTHERAPEUTICS | 4,050 | 0,00 % | Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,84 | 0,00 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 42,390 | 0,00 % | If You Invested $100 In Cogent Biosciences Stock 5 Years Ago, You Would Have This Much Today | ||
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,770 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 361,08 | +0,09 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DYNE THERAPEUTICS | 26,250 | 0,00 % | PetAg expands Tractor Supply distribution of supplements, life-stage nutrition: The company's Dyne Soft Chews and Esbilac ... | ||
| BEAM THERAPEUTICS | 27,480 | 0,00 % | Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Updated BEAM-302 Phase 1/2 Clinical Data Selected for Late-Breaking Oral Presentation at the European Respiratory Society (ERS) Congress 2026 Dosing Complete for All Adult and Adolescent Patients... ► Artikel lesen | |
| TANGO THERAPEUTICS | 27,040 | -0,11 % | Tango Therapeutics, Inc.: Tango Therapeutics Announces Executive Chair Transition | BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 25,290 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| AMYLYX PHARMACEUTICALS | 22,820 | 0,00 % | Amylyx anticipates Phase III LUCIDITY top-line data in late August or early September with $250.8M cash runway into 2028 |
Das Unternehmen OBSIDIAN THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 27,080 Euro und damit -1,53 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OBSIDIAN THERAPEUTICS INC finden Sie auf Wallstreet Online.